IRLAB is granted a patent strengthening the market exclusivity of the drug candidate mesdopetam in China

Gothenburg, Sweden, September 4, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company has been granted an additional ‘composition of matter patent’ in China. The patent protects the salt of mesdopetam intended for use in the forthcoming pharmaceutical product and the process of its manufacture. The now granted patent expands the already strong patent protection for mesdopetam – IRLAB’s most advanced drug candidate.

Change in number of shares and votes in IRLAB Therapeutics AB

IRLAB publishes interim report for the period January – June 2025